Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer

Yao, Yuan; Cai, Tiange; Xia, Xi; Zhang, Ronghua; Chiba, Peter; Cai, Yu

doi:10.1080/10717544.2016.1178825

Cited by 115 publications

(71 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, LAAM TC-CQDs have considerable tumour-specific targeting, making it possible to avoid systemic toxicity. Second, owing to their nanoscopic size, LAAM TC-CQDs may not be removed by ABC transporters 39,40 . Third, LAAM TC-CQDs efficiently penetrate the nucleus, making it possible to maximize the efficacy of DNAdamaging chemotherapy.…”

Section: Lat1 Mediates the Internalization Of Laam Tc-cqds Into Cancementioning

confidence: 99%

Targeted tumour theranostics in mice via carbon quantum dots structurally mimicking large amino acids

et al. 2020

Nat Biomed Eng

301

214

View full text Add to dashboard Cite

Strategies for selectively imaging and delivering drugs to tumours typically leverage differentially upregulated surface molecules on cancer cells. Here, we show that intravenously injected carbon quantum dots, functionalized with multiple paired α-carboxyl and amino groups that bind to the large neutral amino acid transporter 1 (which is expressed in most tumours), selectively accumulate in human tumour xenografts in mice and in an orthotopic mouse model of human glioma. The functionalized quantum dots, which structurally mimic large amino acids and can be loaded with aromatic drugs through π-π stacking interactions, enabled-in the absence of detectable toxicity-near-infrared fluorescence and photoacoustic imaging of the tumours and a reduction in tumour burden after the targeted delivery of chemotherapeutics to the tumours. The versatility of functionalization and high tumour selectivity of the quantum dots make them broadly suitable for tumour-specific imaging and drug delivery.

show abstract

Section: Lat1 Mediates the Internalization Of Laam Tc-cqds Into Cancementioning

confidence: 99%

Targeted tumour theranostics in mice via carbon quantum dots structurally mimicking large amino acids

et al. 2020

Nat Biomed Eng

301

214

View full text Add to dashboard Cite

show abstract

“…Size compatibility of PLGA nanoparticles facilitates intracellular internalization and eludes lysosomal compartments, avoiding degradation of the drug and reduction in drug efficiency (35). There are three mechanisms of drug-loaded nanoparticle incorporation into CSCs (i) caveolin-mediated endocytosis, (ii) clathrin-mediated endocytosis, and (iii) passive transport (36). Anticancer drugs encapsulated in nanoparticles can eventually actively or passively target the CSCs, because sustained drug release in the cytoplasm improves therapeutic effect at the target site (35).…”

Section: Discussionmentioning

confidence: 99%

“…Anticancer drugs encapsulated in nanoparticles can eventually actively or passively target the CSCs, because sustained drug release in the cytoplasm improves therapeutic effect at the target site (35). Such modifications additionally reduce systemic toxicity of chemotherapy drugs and bypass certain forms of multidrug resistance (36). In contrast to other formulations like microparticles, hydrogels, and implants, PLGA nanoparticles can be functionally modified to provide multiple efficacies including controlled drug release, cell-specific targeting, and increased cellular uptake (37).…”

Section: Discussionmentioning

confidence: 99%

Enhancing Chemosensitivity of Breast Cancer Stem Cells by Downregulating SOX2 and ABCG2 Using Wedelolactone-encapsulated Nanoparticles

Das

Mukherjee

Chatterjee

et al. 2019

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

A major caveat in the treatment of breast cancer is disease recurrence after therapeutic regime at both local and distal sites. Tumor relapse is attributed to the persistence of chemoresistant cancer stem cells (CSC), which need to be obliterated along with conventional chemotherapy. Wedelolactone, a naturally occurring coumestan, demonstrates anticancer effects in different cancer cells, although with several limitations, and is mostly ineffective against CSCs. To enhance its biological activity in cancer cells and additionally target the CSCs, wedelolactone-encapsulated PLGA nanoparticles (nWdl) were formulated. Initial results indicated that nanoformulation of wedelolactone not only increased its uptake in breast cancer cells and the CSC population, it enhanced drug retention and sustained release within the cells. Enhanced drug retention was achieved by downregula-tion of SOX2 and ABCG2, both of which contribute to drug resistance of the CSCs. In addition, nWdl prevented epithelialto-mesenchymal transition, suppressed cell migration and invasion, and reduced the percentage of breast cancer stem cells (BCSC) in MDA-MB-231 cells. When administered in combination with paclitaxel, which is known to be ineffective against BCSCs, nWdl sensitized the cells to the effects of paclitaxel and reduced the percentage of ALDH þ BCSCs and mammospheres. Furthermore, nWdl suppressed growth of solid tumors in mice and also reduced CD44 þ /CD24 À/low population. Taken together, our data imply that nWdl decreased metastatic potential of BCSCs, enhanced chemosensitivity through coordinated regulation of pluripotent and efflux genes, and thereby provides an insight into effective drug delivery specifically for obliterating BCSCs.

show abstract

“…44 They have been shown to overcome P-gp efflux, act through receptor-mediated endocytosis, and increase intracellular drug concentration with enhanced cytotoxicity in MCF-7/ doxorubicin-resistant cells. 45,46 Moreover, fabricated immune micelles (antibodies bound to the surface of micelles) were also used in breast adenocarcinomas. Treatment of HER-2-positive breast cancer was performed with anti-HER-2 monoclonal antibody (mAb), fabricated with antibody-conjugated lysosomal P (LA-co-TMCC)-g-PEGfuran micelles.…”

Section: Organic Drug Delivery Approaches Micellesmentioning

confidence: 99%

Drug delivery approaches for breast cancer

Singh

Lillard

et al. 2017

IJN

178

View full text Add to dashboard Cite

Breast cancer is one of the most common cancers affecting women worldwide. The controlled release of drugs to the precise site of the disease using a nanocarrier vehicle increases the therapeutic efficiency of the drugs. Nanotechnology-based approaches used to endorse clinical improvement from a disease also help to understand the interaction of malignant cells with their microenvironment. Receptor-based targeting is another approach for drug delivery which is undergoing clinical trials. Nanoparticles (NPs) delivery has been proven to promise high loading capacity, less toxicity, and stability of the drugs or biomolecules compared to traditional chemotherapeutic drugs. The goal of this review is to present the current problems of breast cancer therapy and discuss the NP-based targeting to overcome the hurdles of conventional drug therapy approach.

show abstract

Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer

Cited by 115 publications

References 83 publications

Targeted tumour theranostics in mice via carbon quantum dots structurally mimicking large amino acids

Targeted tumour theranostics in mice via carbon quantum dots structurally mimicking large amino acids

Enhancing Chemosensitivity of Breast Cancer Stem Cells by Downregulating SOX2 and ABCG2 Using Wedelolactone-encapsulated Nanoparticles

Drug delivery approaches for breast cancer

Contact Info

Product

Resources

About